Zefang Lu

872 total citations · 1 hit paper
13 papers, 635 citations indexed

About

Zefang Lu is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Zefang Lu has authored 13 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Hematology. Recurrent topics in Zefang Lu's work include Inflammatory Biomarkers in Disease Prognosis (4 papers), Platelet Disorders and Treatments (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Zefang Lu is often cited by papers focused on Inflammatory Biomarkers in Disease Prognosis (4 papers), Platelet Disorders and Treatments (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Zefang Lu collaborates with scholars based in China, United States and Australia. Zefang Lu's co-authors include Guangjun Nie, Suping Li, Bozhao Li, Feilong Qi, Yinlong Zhang, Junchao Xu, Tianjiao Chu, Jiaqi Xu, Guangna Liu and Jingyan Wei and has published in prestigious journals such as Advanced Materials, Nano Letters and Nature reviews. Cancer.

In The Last Decade

Zefang Lu

11 papers receiving 634 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The dynamic role of platelets in cancer progression and their therapeutic implications

2023 86 citations Suping Li, Zefang Lu et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zefang Lu China	8	313	229	204	121	86	13	635
Bozhao Li China	11	337 1.1×	271 1.2×	216 1.1×	141 1.2×	105 1.2×	20	719
Huaqin Zuo China	9	280 0.9×	192 0.8×	152 0.7×	77 0.6×	73 0.8×	14	481
Claudia Gottstein Germany	16	149 0.5×	354 1.5×	206 1.0×	150 1.2×	198 2.3×	27	856
Kazuto Fukunaga Japan	10	187 0.6×	243 1.1×	226 1.1×	220 1.8×	214 2.5×	10	783
Yixin Zhong China	17	632 2.0×	210 0.9×	242 1.2×	37 0.3×	94 1.1×	21	858
Oscar A. Marcos‐Contreras United States	16	117 0.4×	329 1.4×	174 0.9×	42 0.3×	87 1.0×	30	763
Eva C. Woenne Germany	11	390 1.2×	247 1.1×	225 1.1×	73 0.6×	39 0.5×	12	783
Mohammad Taleb China	9	205 0.7×	164 0.7×	143 0.7×	74 0.6×	45 0.5×	16	380
In San Kim South Korea	12	114 0.4×	273 1.2×	98 0.5×	148 1.2×	106 1.2×	22	646
Jiacheng Chu China	8	247 0.8×	192 0.8×	85 0.4×	98 0.8×	153 1.8×	9	480

Countries citing papers authored by Zefang Lu

Since Specialization

Citations

This map shows the geographic impact of Zefang Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zefang Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zefang Lu more than expected).

Fields of papers citing papers by Zefang Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zefang Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zefang Lu. The network helps show where Zefang Lu may publish in the future.

Co-authorship network of co-authors of Zefang Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Zefang Lu. A scholar is included among the top collaborators of Zefang Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zefang Lu. Zefang Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

1.

Chu, Tianjiao, Bozhao Li, Zefang Lu, et al.. (2025). Personalized 3D Vaccine Integrates Immunotherapy and Antiangiogenic Therapy to Prevent Oral Squamous Cell Carcinoma Recurrence. Advanced Materials. 37(39). e2417708–e2417708.

2.

Wu, Zhouliang, Zefang Lu, Feilong Qi, et al.. (2025). Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of PD-1 blockade therapy. Cell Reports Medicine. 6(3). 101984–101984.

3.

Zhang, Xiuping, Bozhao Li, Zefang Lu, et al.. (2023). Nanoparticle-based combination of LMWH and doxorubicin for the efficient treatment of hepatocellular carcinoma with portal vein tumor thrombus. Nano Today. 49. 101787–101787. 6 indexed citations

4.

Li, Bozhao, Fei Zhu, Zefang Lu, et al.. (2023). Nanoparticle-Based Combination Therapy Enhances Fulvestrant Efficacy and Overcomes Tumor Resistance in ER-Positive Breast Cancer. Cancer Research. 83(17). 2924–2937. 11 indexed citations

5.

Li, Suping, Zefang Lu, Tianjiao Chu, et al.. (2023). The dynamic role of platelets in cancer progression and their therapeutic implications. Nature reviews. Cancer. 24(1). 72–87. 86 indexed citations breakdown →

6.

Li, Bozhao, Zefang Lu, Zhenlin Yang, et al.. (2023). Monitoring circulating platelet activity to predict cancer-associated thrombosis. Cell Reports Methods. 3(7). 100513–100513. 6 indexed citations

7.

Li, Bozhao, Xiuping Zhang, Zhouliang Wu, et al.. (2022). Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug. Advanced Science. 9(20). e2200477–e2200477. 34 indexed citations

8.

Wu, Zhouliang, Feilong Qi, Bozhao Li, et al.. (2022). Identification of protein kinase C beta as a therapeutic target for neuroendocrine prostate cancer and development of a nanoparticle-based therapeutic strategy. Nano Today. 48. 101705–101705. 3 indexed citations

9.

Li, Bozhao, Tianjiao Chu, Jingyan Wei, et al.. (2021). Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment. Nano Letters. 21(6). 2588–2595. 125 indexed citations

10.

Li, Bozhao, Jingyan Wei, Chunzhi Di, et al.. (2020). Molecularly engineered truncated tissue factor with therapeutic aptamers for tumor-targeted delivery and vascular infarction. Acta Pharmaceutica Sinica B. 11(7). 2059–2069. 18 indexed citations

11.

Qi, Feilong, Meifang Wang, Bozhao Li, et al.. (2020). Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells. Acta Pharmacologica Sinica. 41(7). 895–901. 30 indexed citations

12.

Li, Suping, Yinlong Zhang, Shih‐Hsin Ho, et al.. (2020). Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles. Nature Biomedical Engineering. 4(7). 732–742. 124 indexed citations

13.

Xu, Junchao, Yinlong Zhang, Jiaqi Xu, et al.. (2019). Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models. Advanced Materials. 32(4). e1905145–e1905145. 192 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact